Annual CFF
$82.39 M
+$80.74 M+4884.51%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual cash flow from financing activities is $82.39 million, with the most recent change of +$80.74 million (+4884.51%) on December 31, 2023.
- During the last 3 years, VYNE annual CFF has risen by +$20.59 million (+33.31%).
- VYNE annual CFF is now -34.56% below its all-time high of $125.91 million, reached on December 31, 2018.
Performance
VYNE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$2000.00
+$1000.00+33.33%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly cash flow from financing activities is -$2000.00, with the most recent change of +$1000.00 (+33.33%) on September 30, 2024.
- Over the past year, VYNE quarterly CFF has increased by +$1000.00 (+33.33%).
- VYNE quarterly CFF is now -100.00% below its all-time high of $125.39 million, reached on March 31, 2018.
Performance
VYNE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$82.65 M
+$45.00 K+0.05%
September 30, 2024
Summary
- As of February 8, 2025, VYNE TTM cash flow from financing activities is $82.65 million, with the most recent change of +$45.00 thousand (+0.05%) on September 30, 2024.
- Over the past year, VYNE TTM CFF has increased by +$45.00 thousand (+0.05%).
- VYNE TTM CFF is now -52.75% below its all-time high of $174.91 million, reached on June 30, 2018.
Performance
VYNE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VYNE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4884.5% | +33.3% | +0.1% |
| 3 y3 years | +33.3% | -101.0% | +4900.2% |
| 5 y5 years | -34.6% | -101.0% | +4900.2% |
VYNE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +4884.5% | -100.0% | +99.1% | at high | +356.7% |
| 5 y | 5-year | at high | +4884.5% | -100.0% | +100.0% | -38.9% | +356.7% |
| alltime | all time | -34.6% | -100.0% | -100.0% | +100.0% | -52.8% | +356.7% |
VYNE Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2000.00(-33.3%) | $82.65 M(+0.1%) |
| Jun 2024 | - | -$3000.00(-25.0%) | $82.61 M(+0.0%) |
| Mar 2024 | - | -$4000.00(-100.0%) | $82.61 M(+0.3%) |
| Dec 2023 | $82.39 M(+4884.5%) | $82.66 M(<-9900.0%) | $82.39 M(<-9900.0%) |
| Sep 2023 | - | -$47.00 K(+840.0%) | -$61.00 K(+52.5%) |
| Jun 2023 | - | -$5000.00(-97.7%) | -$40.00 K(-58.3%) |
| Mar 2023 | - | -$217.00 K(-204.3%) | -$96.00 K(-105.8%) |
| Dec 2022 | $1.65 M(-95.8%) | $208.00 K(-900.0%) | $1.65 M(+17.5%) |
| Sep 2022 | - | -$26.00 K(-57.4%) | $1.41 M(-104.4%) |
| Jun 2022 | - | -$61.00 K(-104.0%) | -$32.13 M(-0.2%) |
| Mar 2022 | - | $1.53 M(-4131.6%) | -$32.19 M(-180.9%) |
| Dec 2021 | $39.78 M(-35.6%) | -$38.00 K(-99.9%) | $39.78 M(-16.8%) |
| Sep 2021 | - | -$33.56 M(>+9900.0%) | $47.80 M(-41.3%) |
| Jun 2021 | - | -$129.00 K(-100.2%) | $81.44 M(-39.8%) |
| Mar 2021 | - | $73.50 M(+821.1%) | $135.17 M(+118.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $61.81 M(+1137.6%) | $7.98 M(+9631.7%) | $61.81 M(+15.1%) |
| Sep 2020 | - | $82.00 K(-99.8%) | $53.70 M(-0.2%) |
| Jun 2020 | - | $53.61 M(>+9900.0%) | $53.79 M(+2438.5%) |
| Mar 2020 | - | $140.00 K(-210.2%) | $2.12 M(-57.6%) |
| Dec 2019 | $4.99 M(-96.0%) | -$127.00 K(-173.8%) | $4.99 M(-2.5%) |
| Sep 2019 | - | $172.00 K(-91.1%) | $5.12 M(-5.8%) |
| Jun 2019 | - | $1.93 M(-35.9%) | $5.44 M(+53.7%) |
| Mar 2019 | - | $3.02 M(>+9900.0%) | $3.54 M(-97.2%) |
| Dec 2018 | $125.91 M(+154.4%) | $2000.00(-99.6%) | $125.91 M(+0.7%) |
| Sep 2018 | - | $488.00 K(+1335.3%) | $125.04 M(-28.5%) |
| Jun 2018 | - | $34.00 K(-100.0%) | $174.91 M(+0.0%) |
| Mar 2018 | - | $125.39 M(<-9900.0%) | $174.88 M(+253.4%) |
| Dec 2017 | $49.49 M(>+9900.0%) | -$870.00 K(-101.7%) | $49.49 M(-1.7%) |
| Sep 2017 | - | $50.36 M | $50.36 M |
| Dec 2016 | $0.00(-100.0%) | - | - |
| Dec 2015 | $47.72 M | - | - |
FAQ
- What is VYNE Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for VYNE Therapeutics?
- What is VYNE Therapeutics annual CFF year-on-year change?
- What is VYNE Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly CFF year-on-year change?
- What is VYNE Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for VYNE Therapeutics?
- What is VYNE Therapeutics TTM CFF year-on-year change?
What is VYNE Therapeutics annual cash flow from financing activities?
The current annual CFF of VYNE is $82.39 M
What is the all time high annual CFF for VYNE Therapeutics?
VYNE Therapeutics all-time high annual cash flow from financing activities is $125.91 M
What is VYNE Therapeutics annual CFF year-on-year change?
Over the past year, VYNE annual cash flow from financing activities has changed by +$80.74 M (+4884.51%)
What is VYNE Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VYNE is -$2000.00
What is the all time high quarterly CFF for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly cash flow from financing activities is $125.39 M
What is VYNE Therapeutics quarterly CFF year-on-year change?
Over the past year, VYNE quarterly cash flow from financing activities has changed by +$1000.00 (+33.33%)
What is VYNE Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VYNE is $82.65 M
What is the all time high TTM CFF for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM cash flow from financing activities is $174.91 M
What is VYNE Therapeutics TTM CFF year-on-year change?
Over the past year, VYNE TTM cash flow from financing activities has changed by +$45.00 K (+0.05%)